Loading…
No business profile yet.
Size Symbiotec Pharmalab (SYMBIOTEC.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.12B, the 567th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,621 on 18 Nov 2026.
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | ₹7.36B | ₹7.00B | ₹5.51B |
| Revenue growth | — | — | +5% | +27% | — |
| Gross profit | n/a | n/a | ₹2.04B | ₹1.73B | ₹788M |
| EBITDA | n/a | n/a | ₹1.91B | ₹1.60B | ₹592M |
| Net income | n/a | n/a | ₹968M | ₹1.00B | ₹235M |
| Free cash flow | n/a | n/a | -₹2.75B | -₹290M | -₹1.61B |
| Capital expenditure | n/a | n/a | ₹3.08B | ₹2.10B | ₹2.24B |
| Total debt | ₹3.36B | n/a | ₹5.44B | ₹2.51B | ₹2.20B |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SYMBIOTEC.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +30.9% | -2.3% | highest of 21 |
| Distance from 52-week high | -2.6% | -33.1% | highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.12B | n/a | n/a | n/a | n/a | n/a | n/a |
| Viyash Scientific VIYASH.NS | India | $1.11B | +3% | +124% | 13% | 2.9× | 36.3% | +20.4% |
| GC Biopharma 006280.KS | South Korea | $1.12B | -10% | -3% | 4% | 1.2× | n/a | n/a |
| ST Pharm 237690.KS | South Korea | $1.11B | -51% | +26% | 18% | 3.5× | 4.2% | +21.7% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.11B | -7% | -9% | 11% | 2.3× | 4.9% | +11.3% |
| Vetoquinol VETO.PA | France | $1.10B | +19% | -1% | 15% | 1.5× | -3.6% | +4.2% |
| Cosmo CMHC.SW | Switzerland | $1.13B | -30% | -45% | -13% | 8.2× | n/a | n/a |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.14B | -12% | -2% | 15% | 4.2× | 3.4% | -1.2% |
| PYC Therapeutics PYC.AX | Australia | $1.09B | +29% | n/a | n/a | n/a | n/a | n/a |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 1.4× | n/a | n/a |
| MedinCell MEDCL.PA | France | $1.09B | +4% | -23% | -131% | 49.6× | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.08B | -12% | -21% | 5% | 2.4× | 1.0% | -4.2% |
| Omeros OMER | United States | $1.08B | +24% | n/a | -56% | 17.3× | n/a | n/a |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 2.6× | -4.0% | -9.0% |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | 13.2× | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | 13.3× | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | 8.6× | n/a | n/a |
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 3.0× | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 7.6× | n/a | n/a |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 8.1× | 40.8% | +13.8% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | 1.5× | 2.5% | +6.5% |